ReviewChest2019
Clinical Approach to the Therapy of Asthma-COPD Overlap.
Review in Chest, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Routine Blood Biomarkers and Lung Function in Asthma-COPD Overlap versus Asthma-Only Among Hospitalized Asthma Patients: A Retrospective Cross-Sectional Study.International journal of chronic obstructive pulmonary disease · 2026Article
- Comparative effectiveness of omalizumab in asthma-COPD overlap vs. asthma: a retrospective cohort study.Frontiers in medicine · 2026Article
- Thermal Stability of Dexamethasone-Evaluation with Regard to Modern Medicinal and Pharmaceutical 3D-Printing Applications.Molecules (Basel, Switzerland) · 2025Article
- Phenotyping asthma with airflow obstruction in middle-aged and older adults: a CADSET clinical research collaboration.BMJ open respiratory research · 2023Article
- Effects of a Peptide Derived from the Primary Sequence of a Kallikrein Inhibitor Isolated fromInternational journal of molecular sciences · 2023Article
- Current Perspectives of Pharmacotherapies for COPD.Respiratory care · 2023Article
- COPD Patients with Asthma Features in Vietnam: Prevalence and Suitability for Personalized Medicine.Journal of personalized medicine · 2023Article
- Article
- Glucocorticoids and COVID-19.Pharmacological research · 2022Review
- Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study.American journal of respiratory and critical care medicine · 2022Observational
- Chinese herbal component, Praeruptorin E, enhances anti-asthma efficacy and prevents toxicity of aminophylline by targeting the NF-κB/PXR/CYP3A4 pathway.Annals of translational medicine · 2022Article
- Herbal Medicines for the Treatment of Chronic Obstructive Airway Diseases (Asthma or Chronic Obstructive Pulmonary Disease): A Prospective Observational Study.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Epidemiology, Healthcare Resource Utilization, and Mortality of Asthma and COPD in COVID-19: A Systematic Literature Review and Meta-Analyses.Journal of asthma and allergy · 2022Article
- Review
- ACO (Asthma-COPD Overlap) Is Independent from COPD: The Case in Favour.Diagnostics (Basel, Switzerland) · 2021Review
- Transcriptomic Signature of Asthma-Chronic Obstructive Pulmonary Disease Overlap in Whole Blood.American journal of respiratory cell and molecular biology · 2021Article
- Cardiorespiratory coupling is associated with exercise capacity in patients with chronic obstructive pulmonary disease.BMC pulmonary medicine · 2021Observational
- Serum Concentration of the Phytohormone Abscisic Acid Is Associated With Immune-Regulatory Mediators and Is a Potential Biomarker of Disease Severity in Chronic Obstructive Pulmonary Disease.Frontiers in medicine · 2021Article
- Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases.Frontiers in pharmacology · 2021Review
- Update on Asthma-COPD Overlap (ACO): A Narrative Review.International journal of chronic obstructive pulmonary disease · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Over the last few years, there has been a renewed interest in patients with characteristics of both asthma and COPD. Although the precise definition of asthma-COPD overlap (ACO) is still controversial, patients with overlapping features are frequently encountered in clinical practice, and may indeed have worse clinical outcomes and increased health-care utilization than those with asthma or COPD. Therefore, there is a critical need to set a framework for the therapeutic approach of such patients. There are key distinctions in the therapy between asthma and COPD, particularly regarding the initial choice of therapy. However, there is considerable overlap in the use of existing medications for both diseases. Furthermore, novel therapies approved for asthma, such as monoclonal antibodies, may have a role in patients with COPD and ACO. The use of biomarkers, such as peripheral blood eosinophils, exhaled nitric oxide, and serum IgE, may help in selecting appropriate therapies for ACO. In this review, we provide an overview of available treatments for both asthma and COPD and explore their potential role in the treatment of patients with ACO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.